nach oben

Erschienen in:

05.01.2022 | Original Article

The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents

verfasst von: Carlos Zamora Atenza, Geòrgia Anguera, Mariona Riudavets Melià, Letícia Alserawan De Lamo, Ivana Sullivan, Andrés Barba Joaquin, Jorgina Serra Lopez, M. Angels Ortiz, Maria Mulet, Sílvia Vidal, Margarita Majem

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Tumor PD-L1 expression is a predictive biomarker for patients with NSCLC receiving PD-(L)1 blockade agents. However, although increased tumor PD-L1 expression predicts responsiveness, clinical benefit has been observed regardless of tumor PD-L1 expression, suggesting the existence of other PD-L1 sources. The aim of our study was to analyze whether integrating systemic and tumor PD-L1 is more predictive of efficacy in patients with advanced NSCLC receiving PD-(L)1 blockade agents.

Material and methods

Twenty-nine healthy donors and 119 consecutive patients with advanced NSCLC treated with PD-(L)1 drug were prospectively included. Pretreatment blood samples were collected to evaluate PD-L1 levels on circulating immune cells, platelets (PLTs), platelet microparticles (PMPs), and the plasma soluble PD-L1 concentration (sPD-L1). Tumor PD-L1 status was assessed by immunohistochemistry. The percentages of circulating PD-L1 + leukocytes, sPD-L1 levels, and tumor PD-L1 were correlated with efficacy.

Results

No differences in the percentages of circulating PD-L1 + leukocytes were observed according to tumor PD-L1 expression. Significantly longer progression-free survival was observed in patients with higher percentages of PD-L1 + CD14 + , PD-L1 + neutrophils, PD-L1 + PLTs, and PD-L1 + PMPs and significantly longer overall survival was observed in patients with higher percentages of PD-L1 + CD14 + and high tumor PD-L1 expression. Integrating the PD-L1 data of circulating and tumor PD-L1 results significantly stratified patients according to the efficacy of PD-(L1) blockade agents.

Conclusions

Our results suggest that integrating circulating PD-L1 + leukocytes, PLT, PMPs, and sPD-L1 and tumor PD-L1 expression may be helpful to decide on the best treatment strategy in patients with advanced NSCLC who are candidates for PD-(L)1 blockade agents.

Nur mit Berechtigung zugänglich

Nixon NA, Blais N, Ernst S et al (2018) Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr Oncol 25:e373–e384. https://doi.org/10.3747/co.25.3840CrossRefPubMedPubMedCentral

Bocanegra A, Blanco E, Fernandez-Hinojal G et al (2020) PD-L1 in systemic immunity: unraveling its contribution to PD-1/PD-L1 blockade immunotherapy. Int J Mol Sci 21:1–17CrossRef

Hui R, Gandhi L, Carcereny Costa E et al (2016) Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). J Clin Oncol 34:9026–9026. https://doi.org/10.1200/jco.2016.34.15_suppl.9026CrossRef

Hartley G, Regan D, Guth A, Dow S (2017) Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-α. Cancer Immunol Immunother 66:523–535. https://doi.org/10.1007/s00262-017-1955-5CrossRefPubMedPubMedCentral

Hallqvist A, Rohlin A, Raghavan S (2020) Immune checkpoint blockade and biomarkers of clinical response in non–small cell lung cancer. Scand J Immunol 92. https://doi.org/10.1111/sji.12980

Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in Cancer. N Engl J Med 366:2443–2454. https://doi.org/10.1056/nejmoa1200690CrossRefPubMedPubMedCentral

Cottrell TR, Taube JM (2018) PD-L1 and emerging biomarkers in immune checkpoint blockade therapy. Cancer J (United States) 24:41–46

Prelaj A, Tay R, Ferrara R et al (2019) Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer 106:144–159CrossRef

Riudavets M, Auclin E, Mezquita L (2020) Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations. Futur Oncol 16:1665–1668

10.

Chen DS, Mellman I (2013) Oncology meets immunology: The cancer-immunity cycle. Immunity 39:1–10CrossRef

11.

Ilié M, Szafer-Glusman E, Hofman V et al (2018) Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol 29:193–199. https://doi.org/10.1093/annonc/mdx636CrossRefPubMed

12.

Arrieta O, Montes-Servín E, Hernandez-Martinez JM, et al (2017) Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget 8:101994–102005. https://doi.org/10.18632/oncotarget.22025

13.

Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M et al (2019) PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer. Int J Mol Sci 20. https://doi.org/10.3390/ijms20071631

14.

Rolfes V, Idel C, Pries R, et al (2018) PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. Oncotarget 9:27460–27470. https://doi.org/10.18632/oncotarget.25446

15.

Okuma Y, Wakui H, Utsumi H et al (2018) Soluble programmed cell death ligand 1 as a novel biomarker for nivolumab therapy for non–small-cell lung cancer. Clin Lung Cancer 19:410-417.e1. https://doi.org/10.1016/j.cllc.2018.04.014CrossRefPubMed

16.

Zhou J, Mahoney KM, Giobbie-Hurder A et al (2017) Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res 5:480–492. https://doi.org/10.1158/2326-6066.CIR-16-0329CrossRefPubMedPubMedCentral

17.

Orme JJ, Jazieh KA, Xie T et al (2020) ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology 9. https://doi.org/10.1080/2162402X.2020.1744980

18.

Chen G, Huang AC, Zhang W et al (2018) (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nat 5607718(560):382–386. https://doi.org/10.1038/s41586-018-0392-8CrossRef

19.

Orme JJ, Enninga EAL, Lucien-Matteoni F et al (2020) Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. J Immunother cancer 8:1–7. https://doi.org/10.1136/jitc-2020-001113CrossRef

20.

Ando K, Hamada K, Watanabe M, et al (2019) Plasma levels of soluble PD-L1 correlate with tumor regression in patients with lung and gastric cancer treated with immune checkpoint inhibitors. Anticancer Res 39:5195–5201. https://doi.org/10.21873/anticanres.13716

21.

Costantini A, Julie C, Dumenil C et al (2018) Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. Oncoimmunology 7. https://doi.org/10.1080/2162402X.2018.1452581

22.

Ahmad F, Hong HS, Jäckel M et al (2014) High frequencies of polyfunctional CD8+ NK Cells in Chronic HIV-1 infection are associated with slower disease progression. J Virol 88:12397. https://doi.org/10.1128/JVI.01420-14CrossRefPubMedPubMedCentral

23.

Lindgren Å, Yun CH, Lundgren A et al (2010) CD8- natural killer cells are greatly enriched in the human gastrointestinal tract and have the capacity to respond to bacteria. J Innate Immun 2:294–302. https://doi.org/10.1159/000286238CrossRefPubMed

24.

Bazhin AV, von Ahn K, Fritz J et al (2018) Interferon-α up-regulates the expression of PD-L1 molecules on immune cells through STAT3 and p38 signaling. Front Immunol 9:2129. https://doi.org/10.3389/fimmu.2018.02129CrossRefPubMedPubMedCentral

25.

Munir S, Lundsager MT, Jørgensen MA, et al (2019) Inflammation induced PD-L1-specific T cells. Cell Stress 3:319–327. https://doi.org/10.15698/cst2019.10.201

26.

de Kleijn S, Langereis JD, Leentjens J et al (2013) IFN-γ-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. PLoS ONE 8. https://doi.org/10.1371/journal.pone.0072249

27.

Maine CJ, Aziz NHA, Chatterjee J et al (2014) Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother 63:215–224. https://doi.org/10.1007/s00262-013-1503-xCrossRefPubMed

28.

Wang WB, Yen ML, Liu KJ et al (2015) Interleukin-25 mediates transcriptional control of PD-L1 via STAT3 in multipotent human mesenchymal stromal cells (hMSCs) to suppress Th17 responses. Stem Cell Reports 5:392–404. https://doi.org/10.1016/j.stemcr.2015.07.013CrossRefPubMedPubMedCentral

29.

Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265. https://doi.org/10.1016/S0140-6736(16)32517-XCrossRefPubMed

30.

Gong L, Cai Y, Zhou X, Yang H (2012) Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1. Pathol Oncol Res 18:989–996. https://doi.org/10.1007/s12253-012-9531-yCrossRefPubMed

31.

Meyo MT, Jouinot A, Giroux-Leprieur E et al (2020) Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers (Basel) 12. https://doi.org/10.3390/cancers12020473

32.

Zhang J, Gao J, Li Y et al (2015) Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer 6:534–538. https://doi.org/10.1111/1759-7714.12247CrossRefPubMedPubMedCentral

33.

Jacquelot N, Roberti MP, Enot DP et al (2017) Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun 8. https://doi.org/10.1038/s41467-017-00608-2

34.

Brochez L, Meireson A, Chevolet I et al (2018) Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma. Nat Commun 9. https://doi.org/10.1038/s41467-018-05047-1

Titel: The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
verfasst von: Carlos Zamora Atenza
Geòrgia Anguera
Mariona Riudavets Melià
Letícia Alserawan De Lamo
Ivana Sullivan
Andrés Barba Joaquin
Jorgina Serra Lopez
M. Angels Ortiz
Maria Mulet
Sílvia Vidal
Margarita Majem
Publikationsdatum: 05.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 8/2022
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-021-03107-y

A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma

Open Access
Clinical Trial Report

Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma

Original Article

Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer

Open Access
Original Article

Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence

Original Article

Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells

Original Article

Checkpointhemmer und COVID-19-Impfung – erhöhte Nebenwirkungsrate?

Open Access
COVID-19
Nachrichten

Neu im Fachgebiet Onkologie

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

22.01.2025
Prostatakarzinom
Nachrichten

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

Bei Achalasie auf Candidiasis der Speiseröhre achten!

21.01.2025
Achalasie
Nachrichten

Bei Achalasie-Betroffenen sollte man immer auch auf Candida-Infektionen achten, warnen Forschende aus Rotterdam. In ihrer Studie ließ die Pilzinfektion das Risiko für ein Ösophaguskarzinom massiv steigen.

Adipositas als negativer Prognosefaktor bei Kindern mit Krebs

Eine kanadische Studie weist darauf hin, dass Übergewicht zum Zeitpunkt der Krebsdiagnose ein unabhängiger Risikofaktor für schlechtere Überlebenschancen bei erkrankten Kindern und Jugendlichen sein könnte. Allerdings sind nicht alle Patientinnen und Patienten gleichermaßen betroffen.

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

20.01.2025
Risikofaktoren für Krebserkrankungen
Nachrichten

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents